WOCKPHARMA

Jan 13 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - ZAYNICH ACHIEVES OVER 97% EFFICACY IN CLINICAL STUDY

Source text: ID:nNSE47dchr

Further company coverage: WCKH.NS

(([email protected];))

** Shares of pharma co Wockhardt WCKH.NS rise as much as 9.4% to highest since Dec. 2015 to 1,582.95 rupees

** Co on Thursday said Indian drug regulator approved co's antibiotic drug Miqnaf for treatment of pneumonia

** WCKH shares on track for fourth straight week of gains

** WCKH shares jumped more than three-fold last year vs 39% gains in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Jan 2 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - INDIAN DRUG REGULATOR APPROVES WOCKHARDT'S ANTIBIOTIC MIQNAF

Source text: ID:nBSE68Xcxt

Further company coverage: WCKH.NS

(([email protected];))

Dec 16 (Reuters) - Wockhardt Ltd WCKH.NS:

• ZAYNICH ENABLES SUCCESSFUL LIVER TRANSPLANT FOR US CANCER PATIENT

Source text: ID:nBSE2ctvdc

Further company coverage: WCKH.NS

(([email protected];;))

** Wockhardt WCKH.NS climbs ~2.5% to 1,210 rupees

** Pharmaceutical co's Q2 consol net loss narrows to 220 mln rupees ($2.6 mln) from year-ago loss of 770 mln rupees

** Revenue up 7.4%; expenses largely flat

** WCKH was down ~3% ahead of the results

** Stock has nearly tripled in 2024

($1 = 84.3700 Indian rupees)

(Reporting by Nishit Navin)

(([email protected];))

** Wockhardt WCKH.NS rises 5%, hitting the upper limit of exchange-allowed trading band, to 1,208.35 rupees

** About 349,616 shares traded in five block deals at a premium of 3.8%-5% to last close - LSEG

** Overall 1.02 mln shares traded, 3x the 30-day average

** WCKH up ~185% YTD

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Wockhardt Ltd WCKH.NS rise as much as 4.3% to 1,126.50 rupees

** Pharma co says it has filed fast-acting insulin analog, Aspart injection, ASPARAPID with the Drugs Controller General of India for regulatory approval of licences

** Stock on track to gain for 4th straight day

** More than 338,000 shares traded as of 10:19 a.m. IST, vs their 30-day moving avg of 253,517 shares

** WCKH last up 1.8%, adding to YTD gains of ~159% so far

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Oct 11 (Reuters) - Wockhardt Ltd WCKH.NS:

• NAFITHROMYCIN GETS FAVOURABLE RECOMMENDATION FROM CDSCO

Source text for Eikon: ID:nNSE5QlT87

Further company coverage: WCKH.NS

(([email protected];;))

Oct 7 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - WCK 6777 GRANTED FAST TRACK DESIGNATION BY US FDA, COMPLETES PHASE I STUDY

Source text for Eikon: ID:nBSE3D2wSM

Further company coverage: WCKH.NS

(([email protected];))

Sept 19 (Reuters) - Wockhardt Ltd WCKH.NS:

• CO'S INVESTIGATIONAL DRUG, ZAYNICH CURES COMPLEX CASE OF MENINGITIS

Source text for Eikon: [ID:]

Further company coverage: WCKH.NS

(([email protected];;))

Sept 6 (Reuters) - Wockhardt Ltd WCKH.NS:

• CLARIFIES ON ALLEGATIONS PERTAINING TO PAYMENT OF RENT BY CAROL INFO SERVICES

• CATEGORICALLY DENY ALLEGATIONS

• THESE ALLEGATIONS ARE COMPLETELY "BASELESS AND MISLEADING"

Source text for Eikon: ID:nBSE8MPBKc

Further company coverage: WCKH.NS

(([email protected];;))

** Shares of pharmaceuticals company Wockhardt WCKH.NS rise 3.5% to 990 rupees

** Stock on track for fourth straight session of gains

** Co reports narrower Q1 loss of 140 mln rupees ($1.7 mln) from loss of 1.34 bln rupees year ago, helped by new launches

** Larger rival Sun Pharmaceutical SUN.NS beat Q1 profit estimates earlier this month

** WCKH up 130% YTD, while Nifty Pharma index .NIPHARM which includes SUN and WCKH's other peers, is up by around 32%

** WCKH is not part of the Pharma index

($1 = 83.9340 Indian rupees)

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Aug 9 (Reuters) - Wockhardt Ltd WCKH.NS:

• JUNE-QUARTER CONSOL NET LOSS AFTER TAX 140 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.39 BILLION RUPEES

Source text for Eikon: ID:nBSE9DDsS3

Further company coverage: WCKH.NS

(([email protected];))

** Shares of pharma and biotech co Wockhardt WCKH.NS rise as much as 12% to 943 rupees, highest since August 5, 2016

** Stock on track for an eleventh consecutive session of gain, if trends hold

** On Monday, WCKH's shares rose an exchange-allowed maximum of 20% after its antibiotic drug Zaynich successfully treated a cancer patient in the U.S.

** Share price above 50-day, 100-day and 200-day exponential moving averages since June 19

** Trading vol 2.9x 30-day daily avg

** Stock rose 17.2% in June quarter, its third straight quarterly rise

** Stock last up 6.7%, pushing YTD gains to 111.5%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of pharma and biotech co Wockhardt WCKH.NS rise an exchange-allowed maximum of 20% to 823.9 rupees

** Co said its antibiotic drug Zaynich successfully treated a cancer patient in the U.S. with chronic bilateral thigh infection

** The U.S. Clinical and Laboratory Standards Institutes (CLSI) grants high susceptibility breakpoint to the drug on its success

** Susceptibility breakpoint is a key metric for doctors to recognize most effective antibiotics

** Stock eyes busiest trading session since mid-Feb, over 5.5 mln shares traded

** Including session's gains, stock up ~94% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

June 28 (Reuters) - Wockhardt Ltd WCKH.NS:

• SUCCESSFUL USE OF INVESTIGATIONAL ANTIBIOTIC, ZAYNICH TO TREAT CANCER PATIENT IN U.S. WITH CHRONIC BILATERAL THIGH INFECTION

Source text for Eikon: ID:nNSE6DLzsQ

Further company coverage: WCKH.NS

(([email protected];))

May 28 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - RE-APPOINTS HABIL KHORAKIWALA AS EXECUTIVE CHAIRMAN

• WOCKHARDT LTD - APPROVED RAISING OF FUNDS

• WOCKHARDT LTD MARCH-QUARTER CONSOL LOSS AFTER TAX 1.69 BILLION RUPEES VERSUS LOSS 2.08 BILLION RUPEES

• WOCKHARDT LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7 BILLION RUPEES VERSUS 6.78 BILLION RUPEES

Source text for Eikon: ID:nNSEM5d4D

Further company coverage: WCKH.NS

(([email protected];))

May 21 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - TO CONSIDER RAISING OF FUNDS

Source text for Eikon: ID:nBSE8tZHTq

Further company coverage: WCKH.NS

(([email protected];))

** Shares of India's Wockhardt WCKH.NS up 3% after jumping 4.4% earlier in the session

** The drugmaker launched share sale to institutional investors on Wednesday, approved floor price of issue at 544.02 rupees per share

** Co stock on track to snap two straight weekly losses

** YTD, stock has risen ~32% after a 90% jump in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Feb 14 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT DEC-QUARTER CONSOL NET LOSS 830 MILLION RUPEES VERSUS LOSS 960 MILLION RUPEES

• WOCKHARDT LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.01 BILLION RUPEES VERSUS 6.99 BILLION RUPEES

Source text for Eikon: ID:nBSE9RL6Sf

Further company coverage: WCKH.NS

(([email protected];;))

Feb 7 (Reuters) - Hong Kong-listed Sino Biopharmaceutical 1177.HK will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the company said late on Tuesday.

Sino Biopharmaceutical will keep a 26% stake in CP Qingdao after the disposal, the pharmaceutical conglomerate said in a filing to the Hong Kong Stock Exchange.

CP Qingdao, established in China, is mainly involved in research and development, production and sale of osteoporosis medicines and marine pharmaceuticals.

Through the deal, Guoxin Group plans to enter the life and health industry characterised with marine biological pharmaceuticals, Sino Biopharmaceutical said.

The company expects to record a gain of about 1.60 billion yuan on the disposal, subject to audit.

($1 = 7.1858 Chinese yuan)

(Reporting by Himanshi Akhand in Bengaluru; Editing by Subhranshu Sahu)

(([email protected];))

Dec 11 (Reuters) - Wockhardt Ltd WCKH.NS:

• COMPLETION OF PHASE 3 PNEUMONIA STUDY OF MACROLIDE ANTIBIOTIC NAFITHROMYCIN WCK 4873

Source text for Eikon: ID:nNSEMjgpF

Further company coverage: WCKH.NS

(([email protected];;))

** Shares of pharma and biotechnology co Wockhardt WCKH.NS up as much as 20% at 336.95 rupees, their biggest intraday gain since Nov. 20, 2020

** WCKH at highest level since Feb. 24, 2022

** Over 2.6 mln shares change hands in 8 separate block deals as of 02:23 p.m. IST, at a price between 312-337 rupees apiece - LSEG data

** Nearly 30 mln shares traded by 2:25 p.m. IST, 15.6x the 30-day moving average

** Stock up ~47% YTD

(Reporting by Kashish Tandon)

(([email protected]))

Aug 14 (Reuters) - Wockhardt Ltd WCKH.NS:

• JUNE-QUARTER CONSOL NET LOSS 1.34 BILLION RUPEES VERSUS LOSS 670 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.44 BILLION RUPEES VERSUS 5.95 BILLION RUPEES

Further company coverage: WCKH.NS

(([email protected];))

July 28 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD- GUARDIAN FINANCE CLARIFIES INVOCATION OF PLEDGED SHARES WAS EFFECTED WITHOUT MALAFIDE INTENT

• WOCKHARDT LTD- GUARDIAN FINANCE WOULD BE REINSTATING SHARES BACK

Source text for Eikon: ID:nBSE5lY04

Further company coverage: WCKH.NS

(([email protected];))

May 26 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - RE-APPOINTS MURTAZA KHORAKIWALA AS MANAGING DIRECTOR

Source text for Eikon: ID:nBSE5prS94

Further company coverage: WCKH.NS

(([email protected];))

May 23 (Reuters) - Wockhardt Ltd WCKH.NS:

• GOT SEBI SETTLEMENT ORDER REGARDING SHOW CAUSE NOTICE DATED SEPT 15, 2022

• CHARGES IN SHOW CAUSE NOTICE AGAINST CO, DIRECTORS HAVE BEEN DISPOSED OF

• SETTLEMENT TERMS INCLUDE PAYMENT ON BEHALF OF DIRECTORS

• NO MATERIAL IMPACT OF SETTLEMENT ON CO'S FINANCIAL POSITION

Source text for Eikon: ID:nNSE7ns4Pn

Further company coverage: WCKH.NS

(([email protected];))

May 19 (Reuters) - Wockhardt Ltd WCKH.NS:

• TO CONSIDER RAISING OF FUNDS

Source text for Eikon: ID:nBSEKPZ3C

Further company coverage: WCKH.NS

(([email protected];))